Irene Nkouaze, | |
6475 New Hampshire Ave Ste 504f, Hyattsville, MD 20783-3277 | |
(301) 560-1352 | |
(301) 238-4714 |
Full Name | Irene Nkouaze |
---|---|
Gender | Female |
Speciality | Home Health Aide |
Location | 6475 New Hampshire Ave Ste 504f, Hyattsville, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1386075521 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | 00332 (District Of Columbia) | Secondary |
374U00000X | Home Health Aide | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Irene Nkouaze, 6475 New Hampshire Ave Ste 504f, Hyattsville, MD 20783-3277 Ph: (301) 560-1352 | Irene Nkouaze, 6475 New Hampshire Ave Ste 504f, Hyattsville, MD 20783-3277 Ph: (301) 560-1352 |
News Archive
Scientific breakthroughs in the study of the human genome coupled with online access to massive genealogical records have opened the doors of ancestral investigation to include all those interested in unearthing their roots and, on October 26-27 at the Metropolitan Pavilion in New York City, The Genealogy Event will feature exciting learning opportunities and resources for both novice and professional enthusiasts.
While the incidence of colon cancer has been declining in individuals 50 years old and older in the United States, it is steadily rising in those under age 50. With funding from the U.S. Department of Veterans Affairs, Thomas F. Imperiale, M.D., a VA and Regenstrief Institute clinician-researcher, is developing and validating a model to predict risk for colon cancer in those under 50 with no family history of the disease.
HemaCare Corporation announced today that it has reached a definitive agreement to sell certain assets of its Blood Services operations to the American Red Cross. Under the terms of the sale, which closed today, HemaCare sold its red blood cell collection operation assets to the American Red Cross. The sale does not include HemaCare's platelet collection business.
Anacor Pharmaceuticals announced today that it has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole, a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.
As climate change brings hotter weather to Southern California, coastal populations from San Diego to Santa Barbara may face an increased risk of contracting West Nile virus and other mosquito-borne diseases, suggests a new study led by researchers at the University of California, Berkeley.
› Verified 9 days ago